<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04176250</url>
  </required_header>
  <id_info>
    <org_study_id>Gates MRI-TBD03-201</org_study_id>
    <nct_id>NCT04176250</nct_id>
  </id_info>
  <brief_title>Early Bactericidal Activity of TBA-7371 in Pulmonary Tuberculosis</brief_title>
  <official_title>A Phase 2a, Dose Escalation, Controlled, Randomized Study to Evaluate Safety, Early Bactericidal Activity (EBA) and Pharmacokinetics of TBA-7371 in Adult Patients With Rifampicin-sensitive Pulmonary Tuberculosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bill &amp; Melinda Gates Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bill &amp; Melinda Gates Medical Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, early bactericidal activity (EBA) and&#xD;
      pharmacokinetics of TBA-7371 in adult participants with rifampicin-sensitive tuberculosis and&#xD;
      select dose regimen(s) for future studies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 16, 2020</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Slope of Average Change per Day, From Day 0 to Day 14 [BAcfu (0-14)] of the Log Colony Forming Units (CFU) Counts</measure>
    <time_frame>Day 0 (screening) to Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants who Experienced One or More Severe (≥ grade 3) and/or Serious Adverse Events (SAEs)</measure>
    <time_frame>Day 1 through Day 15</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Slope of Average Change per Day, From Day 0 to Day 2 [BAcfu (0-2)] and From Day 2 to Day 14 [BAcfu (2-14)] of the Log CFU Counts</measure>
    <time_frame>Day 0 (Screening) to Day 2 and Day 2 to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Slope of the Time to Sputum Culture Positivity (TPP) in the Mycobacteria Growth Indicator Tube (MGIT) System From Day 0 to Day 14 [BAttp (0-14)], From Day 0 to Day 2 [BAttp (0-2)], and From Day 2 to Day 14 [BAttp (2-14)]</measure>
    <time_frame>Day 0 (Screening) to Day 14, Day 0 (Screening) to Day 2 and Day 2 to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Slope of the Log Concentration of Sputum LipoArabinoMannan (LAM) From Day 0 to day 14 [BAlam (0-14)], From Day 0 to Day 2 [BAlam (0-2)], and From Day 2 to Day 14 [BAlam (2-14)]</measure>
    <time_frame>Day 0 (Screening) to Day 14, Day 0 (Screening) to Day 2 and Day 2 to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AEs) and Frequency of AEs</measure>
    <time_frame>Day 1 through Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Participants With Any New Eye Symptom in One or Both Eyes</measure>
    <time_frame>Day 1 through day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean and Frequency Distribution of Duration of Each Eye Symptom</measure>
    <time_frame>Day 1 through day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean and Frequency Distribution of Percentage of Days With Any Eye Symptom and Each of the Eye Symptoms</measure>
    <time_frame>Day 1 through day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Visual Acuity Score From Screening to Lowest Score</measure>
    <time_frame>Day 1 through day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change in Visual Acuity Score From Screening to Lowest Score</measure>
    <time_frame>Day 1 through day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Changes in Color Vision Score From Screening to Lowest Score</measure>
    <time_frame>Day 1 through day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Changes in Color Vision Score From Screening to Lowest Score</measure>
    <time_frame>Day 1 through day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean and Frequency Distribution of Changes in Heart Rate (HR)</measure>
    <time_frame>Day 1 through day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean and Frequency Distribution of Changes in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)</measure>
    <time_frame>Day 1 through day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With ≥ 25 % Increase in HR, Decrease in SBP, Decrease in DBP</measure>
    <time_frame>Day 1 through day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean and Frequency Distribution of Percentage of Days With ≥ 25% Increase in HR, Decrease in SBP, Decrease in DBP</measure>
    <time_frame>Day 1 through day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean/median Change in PR, RR, QRS, QT, QTcF Values From Baseline ECG</measure>
    <time_frame>Day 0 (screening) Through Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in HR</measure>
    <time_frame>Day 1 to days 4, 7, 10, 14 and 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in SBP and DBP</measure>
    <time_frame>Day 1 to days 4, 7, 10, 14 and 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Number of Participants With Eye Symptoms (All, Severe, Serious)</measure>
    <time_frame>Day 1 to days 4, 7, 10, 14 and 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Visual Acuity Score</measure>
    <time_frame>Day 1 to days 4, 7, 10, 14 and 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Color Vision Score</measure>
    <time_frame>Day 1 to days 4, 7, 10, 14 and 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in HR</measure>
    <time_frame>Day 0 (Screening) to days 28 and 42; and from day 14 to days 28 and 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in SBP and DBP</measure>
    <time_frame>Day 0 (Screening) to days 28 and 42; and from day 14 to days 28 and 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Number of Participants with Eye Symptoms (All, Severe, Serious)</measure>
    <time_frame>Day 0 (Screening) to days 28 and 42; and from days 1-15 (combined) to days 28-42 (combined)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Visual Acuity Score</measure>
    <time_frame>Day 0 (Screening) to days 28 and 42; and from days 1-15 (combined) to days 28-42 (combined)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Color Vision Score</measure>
    <time_frame>Day 0 (Screening) to days 28 and 42; and from days 1-15 (combined) to days 28-42 (combined)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Concentration of Clinical Safety Haematology Parameter: Red Blood Cells</measure>
    <time_frame>Day 0 (Screening), Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Concentration of Clinical Safety Haematology Parameter: Red Blood Cells</measure>
    <time_frame>Day 0 (Screening), Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Screening in Clinical Safety Haematology Parameter: Red Blood Cells</measure>
    <time_frame>Day 0 (Screening) to Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Screening in Clinical Safety Haematology Parameter: Red Blood Cells</measure>
    <time_frame>Day 0 (Screening) to Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Concentration of Clinical Safety Haematology Parameter: Haemoglobin</measure>
    <time_frame>Day 0 (Screening), Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Concentration of Clinical Safety Haematology Parameter: Haemoglobin</measure>
    <time_frame>Day 0 (Screening), Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Screening in Clinical Safety Haematology Parameter: Haemoglobin</measure>
    <time_frame>Day 0 (Screening) to Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Screening in Clinical Safety Haematology Parameter: Haemoglobin</measure>
    <time_frame>Day 0 (Screening) to Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Concentration of Clinical Safety Haematology Parameter: Platelets</measure>
    <time_frame>Day 0 (Screening), Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Concentration of Clinical Safety Haematology Parameter: Platelets</measure>
    <time_frame>Day 0 (Screening), Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Screening in Clinical Safety Haematology Parameter: Platelets</measure>
    <time_frame>Day 0 (Screening) to Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Screening in Clinical Safety Haematology Parameter: Platelets</measure>
    <time_frame>Day 0 (Screening) to Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Concentration of Clinical Safety Haematology Parameter: White Blood Cells</measure>
    <time_frame>Day 0 (Screening), Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Concentration of Clinical Safety Haematology Parameter: White Blood Cells</measure>
    <time_frame>Day 0 (Screening), Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Screening in Clinical Safety Haematology Parameter: White Blood Cells</measure>
    <time_frame>Day 0 (Screening) to Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Screening in Clinical Safety Haematology Parameter: White Blood Cells</measure>
    <time_frame>Day 0 (Screening) to Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Levels of Clinical Safety Haematology Parameter: Neutrophils</measure>
    <time_frame>Day 0 (Screening), Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Levels of Clinical Safety Haematology Parameter: Neutrophils</measure>
    <time_frame>Day 0 (Screening), Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Screening in Clinical Safety Haematology Parameter: Neutrophils</measure>
    <time_frame>Day 0 (Screening) to Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Screening in Clinical Safety Haematology Parameter: Neutrophils</measure>
    <time_frame>Day 0 (Screening) to Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Levels of Clinical Safety Haematology Parameter: Lymphocytes</measure>
    <time_frame>Day 0 (Screening), Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Levels of Clinical Safety Haematology Parameter: Lymphocytes</measure>
    <time_frame>Day 0 (Screening), Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Screening in Clinical Safety Haematology Parameter: Lymphocytes</measure>
    <time_frame>Day 0 (Screening) to Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Screening in Clinical Safety Haematology Parameter: Lymphocytes</measure>
    <time_frame>Day 0 (Screening) to Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Levels of Clinical Safety Haematology Parameter: Monocytes</measure>
    <time_frame>Day 0 (Screening), Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Levels of Clinical Safety Haematology Parameter: Monocytes</measure>
    <time_frame>Day 0 (Screening), Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Screening in Clinical Safety Haematology Parameter: Monocytes</measure>
    <time_frame>Day 0 (Screening) to Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Screening in Clinical Safety Haematology Parameter: Monocytes</measure>
    <time_frame>Day 0 (Screening) to Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Levels of Clinical Safety Haematology Parameter: Eosinophils</measure>
    <time_frame>Day 0 (Screening), Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Levels of Clinical Safety Haematology Parameter: Eosinophils</measure>
    <time_frame>Day 0 (Screening), Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Screening in Clinical Safety Haematology Parameter: Eosinophils</measure>
    <time_frame>Day 0 (Screening) to Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Screening in Clinical Safety Haematology Parameter: Eosinophils</measure>
    <time_frame>Day 0 (Screening) to Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Levels of Clinical Safety Haematology Parameter: Basophils</measure>
    <time_frame>Day 0 (Screening), Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Levels of Clinical Safety Haematology Parameter: Basophils</measure>
    <time_frame>Day 0 (Screening), Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Screening in Clinical Safety Haematology Parameter: Basophils</measure>
    <time_frame>Day 0 (Screening) to Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Screening in Clinical Safety Haematology Parameter: Basophils</measure>
    <time_frame>Day 0 (Screening) to Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Concentration of Clinical Safety Serum Chemistry Parameter: Alanine Aminotransferase</measure>
    <time_frame>Day 0 (Screening), Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Concentration of Clinical Safety Serum Chemistry Parameter: Alanine Aminotransferase</measure>
    <time_frame>Day 0 (Screening), Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Screening in Clinical Safety Serum Chemistry Parameter: Alanine Aminotransferase</measure>
    <time_frame>Day 0 (Screening) to Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Screening in Clinical Safety Serum Chemistry Parameter: Alanine Aminotransferase</measure>
    <time_frame>Day 0 (Screening) to Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Concentration of Clinical Safety Serum Chemistry Parameter: Aspartate Aminotransferase</measure>
    <time_frame>Day 0 (Screening), Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Concentration of Clinical Safety Serum Chemistry Parameter: Aspartate Aminotransferase</measure>
    <time_frame>Day 0 (Screening), Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Screening in Clinical Safety Serum Chemistry Parameter: Aspartate Aminotransferase</measure>
    <time_frame>Day 0 (Screening) to Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Screening in Clinical Safety Serum Chemistry Parameter: Aspartate Aminotransferase</measure>
    <time_frame>Day 0 (Screening) to Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Concentration of Clinical Safety Serum Chemistry Parameter: Alkaline Phosphatase</measure>
    <time_frame>Day 0 (Screening), Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Concentration of Clinical Safety Serum Chemistry Parameter: Alkaline Phosphatase</measure>
    <time_frame>Day 0 (Screening), Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Screening in Clinical Safety Serum Chemistry Parameter: Alkaline Phosphatase</measure>
    <time_frame>Day 0 (Screening) to Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Screening in Clinical Safety Serum Chemistry Parameter: Alkaline Phosphatase</measure>
    <time_frame>Day 0 (Screening) to Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Concentration of Clinical Safety Serum Chemistry Parameter: Total Bilirubin</measure>
    <time_frame>Day 0 (Screening), Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Concentration of Clinical Safety Serum Chemistry Parameter: Total Bilirubin</measure>
    <time_frame>Day 0 (Screening), Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Screening in Clinical Safety Serum Chemistry Parameter: Total Bilirubin</measure>
    <time_frame>Day 0 (Screening) to Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Screening in Clinical Safety Serum Chemistry Parameter: Total Bilirubin</measure>
    <time_frame>Day 0 (Screening) to Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Concentration of Clinical Safety Serum Chemistry Parameter: Creatinine</measure>
    <time_frame>Day 0 (Screening), Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Concentration of Clinical Safety Serum Chemistry Parameter: Creatinine</measure>
    <time_frame>Day 0 (Screening), Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Screening in Clinical Safety Serum Chemistry Parameter: Creatinine</measure>
    <time_frame>Day 0 (Screening) to Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Screening in Clinical Safety Serum Chemistry Parameter: Creatinine</measure>
    <time_frame>Day 0 (Screening) to Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Concentration of Clinical Safety Serum Chemistry Parameter: Blood Urea Nitrogen</measure>
    <time_frame>Day 0 (Screening), Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Concentration of Clinical Safety Serum Chemistry Parameter: Blood Urea Nitrogen</measure>
    <time_frame>Day 0 (Screening), Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Screening in Clinical Safety Serum Chemistry Parameter: Blood Urea Nitrogen</measure>
    <time_frame>Day 0 (Screening) to Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Screening in Clinical Safety Serum Chemistry Parameter: Blood Urea Nitrogen</measure>
    <time_frame>Day 0 (Screening) to Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Concentration of Clinical Safety Serum Coagulation Parameter: Prothrombin Time</measure>
    <time_frame>Day 0 (Screening), Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Concentration of Clinical Safety Serum Coagulation Parameter: Prothrombin Time</measure>
    <time_frame>Day 0 (Screening), Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Screening in Clinical Safety Serum Coagulation Parameter: Prothrombin Time</measure>
    <time_frame>Day 0 (Screening) to Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Screening in Clinical Safety Serum Coagulation Parameter: Prothrombin Time</measure>
    <time_frame>Day 0 (Screening) to Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Concentration of Clinical Safety Serum Coagulation Parameter: Partial Thromboplastin Time</measure>
    <time_frame>Day 0 (Screening), Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Concentration of Clinical Safety Serum Coagulation Parameter: Partial Thromboplastin Time</measure>
    <time_frame>Day 0 (Screening), Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Screening in Clinical Safety Serum Coagulation Parameter: Partial Thromboplastin Time</measure>
    <time_frame>Day 0 (Screening) to Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Screening in Clinical Safety Serum Coagulation Parameter: Partial Thromboplastin Time</measure>
    <time_frame>Day 0 (Screening) to Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Concentration of Clinical Safety Serum Coagulation Parameter: International Normalized Ratio</measure>
    <time_frame>Day 0 (Screening), Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Concentration of Clinical Safety Serum Coagulation Parameter: International Normalized Ratio</measure>
    <time_frame>Day 0 (Screening), Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Screening in Clinical Safety Serum Coagulation Parameter: International Normalized Ratio</measure>
    <time_frame>Day 0 (Screening) to Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Screening in Clinical Safety Serum Coagulation Parameter: International Normalized Ratio</measure>
    <time_frame>Day 0 (Screening) to Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Concentration of Clinical Safety Urinalysis Parameter: Specific Gravity</measure>
    <time_frame>Day 0 (Screening), Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Concentration of Clinical Safety Urinalysis Parameter: Specific Gravity</measure>
    <time_frame>Day 0 (Screening), Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Screening in Clinical Safety Urinalysis Parameter: Specific Gravity</measure>
    <time_frame>Day 0 (Screening) to Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Screening in Clinical Safety Urinalysis Parameter: Specific Gravity</measure>
    <time_frame>Day 0 (Screening) to Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Concentration of Clinical Safety Urinalysis Parameter: Potential of Hydrogen (pH)</measure>
    <time_frame>Day 0 (Screening), Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Concentration of Clinical Safety Urinalysis Parameter: pH</measure>
    <time_frame>Day 0 (Screening), Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Screening in Clinical Safety Urinalysis Parameter: pH</measure>
    <time_frame>Day 0 (Screening) to Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Screening in Clinical Safety Urinalysis Parameter: pH</measure>
    <time_frame>Day 0 (Screening) to Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Concentration of Clinical Safety Urinalysis Parameter: Glucose</measure>
    <time_frame>Day 0 (Screening), Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Concentration of Clinical Safety Urinalysis Parameter: Glucose</measure>
    <time_frame>Day 0 (Screening), Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Screening in Clinical Safety Urinalysis Parameter: Glucose</measure>
    <time_frame>Day 0 (Screening) to Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Screening in Clinical Safety Urinalysis Parameter: Glucose</measure>
    <time_frame>Day 0 (Screening) to Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Concentration of Clinical Safety Urinalysis Parameter: Protein</measure>
    <time_frame>Day 0 (Screening), Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Concentration of Clinical Safety Urinalysis Parameter: Protein</measure>
    <time_frame>Day 0 (Screening), Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Screening in Clinical Safety Urinalysis Parameter: Protein</measure>
    <time_frame>Day 0 (Screening) to Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Screening in Clinical Safety Urinalysis Parameter: Protein</measure>
    <time_frame>Day 0 (Screening) to Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Concentration of Clinical Safety Urinalysis Parameter: Blood</measure>
    <time_frame>Day 0 (Screening), Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Concentration of Clinical Safety Urinalysis Parameter: Blood</measure>
    <time_frame>Day 0 (Screening), Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Screening in Clinical Safety Urinalysis Parameter: Blood</measure>
    <time_frame>Day 0 (Screening) to Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Screening in Clinical Safety Urinalysis Parameter: Blood</measure>
    <time_frame>Day 0 (Screening) to Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Concentration of Clinical Safety Urinalysis Parameter: Ketones</measure>
    <time_frame>Day 0 (Screening), Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Concentration of Clinical Safety Urinalysis Parameter: Ketones</measure>
    <time_frame>Day 0 (Screening), Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Screening in Clinical Safety Urinalysis Parameter: Ketones</measure>
    <time_frame>Day 0 (Screening) to Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Screening in Clinical Safety Urinalysis Parameter: Ketones</measure>
    <time_frame>Day 0 (Screening) to Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Concentration of Clinical Safety Urinalysis Parameter: Bilirubin</measure>
    <time_frame>Day 0 (Screening), Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Concentration of Clinical Safety Urinalysis Parameter: Bilirubin</measure>
    <time_frame>Day 0 (Screening), Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Screening in Clinical Safety Urinalysis Parameter: Bilirubin</measure>
    <time_frame>Day 0 (Screening) to Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Screening in Clinical Safety Urinalysis Parameter: Bilirubin</measure>
    <time_frame>Day 0 (Screening) to Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Concentration of Clinical Safety Urinalysis Parameter: Urobilinogen</measure>
    <time_frame>Day 0 (Screening), Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Concentration of Clinical Safety Urinalysis Parameter: Urobilinogen</measure>
    <time_frame>Day 0 (Screening), Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Screening in Clinical Safety Urinalysis Parameter: Urobilinogen</measure>
    <time_frame>Day 0 (Screening) to Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Screening in Clinical Safety Urinalysis Parameter: Urobilinogen</measure>
    <time_frame>Day 0 (Screening) to Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Concentration of Clinical Safety Urinalysis Parameter: Nitrite</measure>
    <time_frame>Day 0 (Screening), Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Concentration of Clinical Safety Urinalysis Parameter: Nitrite</measure>
    <time_frame>Day 0 (Screening), Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Screening in Clinical Safety Urinalysis Parameter: Nitrite</measure>
    <time_frame>Day 0 (Screening) to Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Screening in Clinical Safety Urinalysis Parameter: Nitrite</measure>
    <time_frame>Day 0 (Screening) to Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Concentration of Clinical Safety Urinalysis Parameter: Leukocyte Esterase</measure>
    <time_frame>Day 0 (Screening), Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Concentration of Clinical Safety Urinalysis Parameter: Leukocyte Esterase</measure>
    <time_frame>Day 0 (Screening), Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Screening in Clinical Safety Urinalysis Parameter: Leukocyte Esterase</measure>
    <time_frame>Day 0 (Screening) to Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Screening in Clinical Safety Urinalysis Parameter: Leukocyte Esterase</measure>
    <time_frame>Day 0 (Screening) to Day 3, Day 7, Day 14 and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TBA7371 Pharmacokinetic Parameter (PK): Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>Days 1, 2, 4, 7 and 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TBA7371 PK Parameter: Time to Maximum Plasma Concentration (Tmax)</measure>
    <time_frame>Days 1, 2, 4, 7 and 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TBA7371 PK Parameter: Last Measurable Concentration (Clast)</measure>
    <time_frame>Days 1, 2, 4, 7 and 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TBA7371 PK Parameter: Time to Last Measurable Concentration (Tlast)</measure>
    <time_frame>Days 1, 2, 4, 7 and 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TBA7371 PK Parameter: Area Under the Plasma Concentration-Time Curve (AUC) Extrapolated to Infinity (AUCinf)</measure>
    <time_frame>Days 1, 2, 4, 7 and 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TBA7371 PK Parameter: Area Under the Plasma Concentration-Time Curve from 0 up to the Last Measurable Concentration (AUClast)</measure>
    <time_frame>Days 1, 2, 4, 7 and 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TBA7371 PK Parameter: AUC to the End of the Dosing Period (AUCtau)</measure>
    <time_frame>Days 1, 2, 4, 7 and 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TBA7371 PK Parameter: Half-Life</measure>
    <time_frame>Days 1, 2, 4, 7 and 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Accumulation Ratios</measure>
    <time_frame>Days 1, 2, 4, 7 and 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expected Concentration Associated With 90% of the Maximal TBA-7371 Early Bactericidal Activity (EBA) Effect (EC90)</measure>
    <time_frame>Day 0 (Screening) to Day 14</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Pulmonary Tuberculosis</condition>
  <arm_group>
    <arm_group_label>TBA-7371 100 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TBA-7371 100 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TBA-7371 200 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TBA-7371 100 mg TID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TBA-7371 400 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HRZE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TBA-7371</intervention_name>
    <description>Participants will receive TBA-7371 oral suspension 100 milligram (mg) once daily (QD) for 14 days.</description>
    <arm_group_label>TBA-7371 100 mg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TBA-7371</intervention_name>
    <description>Participants will receive TBA-7371 oral suspension 100 mg twice daily (BID) for 14 days.</description>
    <arm_group_label>TBA-7371 100 mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TBA-7371</intervention_name>
    <description>Participants will receive TBA-7371 oral suspension 200 mg QD for 14 days.</description>
    <arm_group_label>TBA-7371 200 mg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TBA-7371</intervention_name>
    <description>Participants will receive TBA-7371 oral suspension 100 mg three times daily (TID) for 14 days.</description>
    <arm_group_label>TBA-7371 100 mg TID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TBA-7371</intervention_name>
    <description>Participants will receive TBA-7371 oral suspension 400 mg QD for 14 days.</description>
    <arm_group_label>TBA-7371 400 mg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HRZE</intervention_name>
    <description>Participants will receive Isoniazid [H] / rifampicin [R] / pyrazinamide [Z] / ethambutol [E] (HRZE), a fixed dose combination (H: 75 mg / R: 150 mg / Z: 400 mg / E: 275 mg) tablet QD for 14 days.</description>
    <arm_group_label>HRZE</arm_group_label>
    <other_name>Rifafour® e-275</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants between 18 to 60 years of age inclusive at the time of signing the&#xD;
             informed consent.&#xD;
&#xD;
          -  Body weight within 40 and 100 kilogram (inclusive).&#xD;
&#xD;
          -  Untreated, rifampicin-sensitive pulmonary tuberculosis, as defined by all of the&#xD;
             following:&#xD;
&#xD;
               1. isoniazid urine screen negativity&#xD;
&#xD;
               2. sputum smear positivity on direct microscopy for acid-fast bacilli, defined as at&#xD;
                  least 1+ on the International Unit Against Tuberculosis and Lung Disease/ World&#xD;
                  Health Organization scale&#xD;
&#xD;
               3. chest X-rays which in the opinion of the investigator is consistent with&#xD;
                  tuberculosis (TB).&#xD;
&#xD;
               4. Mycobacterium tuberculosis (Mtb) positivity on molecular test (GeneXpert®)&#xD;
&#xD;
               5. rifampicin sensitivity on molecular test (GeneXpert®).&#xD;
&#xD;
          -  Participants must be able to produce at least 10 milliliter of sputum during the&#xD;
             overnight sputum collection (day -7 to -3 or day -2 of the Screening Phase).&#xD;
&#xD;
          -  Female and male participants should be of non-childbearing potential or using an&#xD;
             effective method of birth control.&#xD;
&#xD;
               -  Non-childbearing potential is defined as follows:&#xD;
&#xD;
                    1. participant is not heterosexually active or practices sexual abstinence, OR&#xD;
&#xD;
                    2. female participant or sexual partner has undergone bilateral oophorectomy,&#xD;
                       bilateral tubal ligation and/or hysterectomy, OR&#xD;
&#xD;
                    3. female participant or sexual partner has been postmenopausal with a history&#xD;
                       of no menses for at least 12 consecutive months, OR&#xD;
&#xD;
                    4. male participant or sexual partner has undergone vasectomy or bilateral&#xD;
                       orchidectomy at least three months prior to screening, OR&#xD;
&#xD;
                    5. male participant with pregnant sexual partner (for duration of the study)&#xD;
                       who does not have any other sexual partners.&#xD;
&#xD;
               -  An effective method of birth control is defined as follows:&#xD;
&#xD;
                    1. double barrier method, which can include any 2 of the following: a male&#xD;
                       condom, diaphragm, cervical cap, or female condom (male and female condoms&#xD;
                       should not be used together), OR&#xD;
&#xD;
                    2. barrier method (one of the above) combined with hormone-based contraceptives&#xD;
                       or an intra-uterine device for the female participant or partner, AND&#xD;
&#xD;
                    3. participant willing to continue practicing one of the above-mentioned birth&#xD;
                       control methods throughout 14-day Study Treatment Phase and for 4 weeks&#xD;
                       after the last dose of study medication or discontinuation from study&#xD;
                       medication in case of early withdrawal.&#xD;
&#xD;
          -  Participants must be capable of giving signed informed consent, which includes&#xD;
             agreeing to compliance with the requirements and restrictions listed in the informed&#xD;
             consent form and the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Need for immediate effective anti-TB treatment as judged by the investigator.&#xD;
&#xD;
          -  Evidence and/or history of extra-thoracic TB (e.g. miliary TB, abdominal TB,&#xD;
             urogenital TB, osteoarthritic TB, TB meningitis, ocular TB), as judged by the&#xD;
             investigator.&#xD;
&#xD;
          -  Evidence and/or history in the last 5 years of one or any combination of the&#xD;
             following:&#xD;
&#xD;
               1. uveitis;&#xD;
&#xD;
               2. color vision deficiency;&#xD;
&#xD;
               3. amblyopia;&#xD;
&#xD;
               4. visual acuity worse than 20/25 after correction in either eye;&#xD;
&#xD;
               5. any known eye disease or prior eye surgery;&#xD;
&#xD;
               6. any systemic condition with ocular manifestations (i.e. Marfan, syphilis,&#xD;
                  diabetes, Beçhet, Vogt-Koyanagi-Harada, Lyme, or chronic inflammatory condition&#xD;
                  such as sarcoidosis, rheumatoid arthritis, psoriatic arthritis)&#xD;
&#xD;
          -  Evidence and/or history in the last 5 years of clinically significant medical&#xD;
             condition(s) as judged by the investigator, including malignancies and unstable or&#xD;
             uncontrolled hypertension.&#xD;
&#xD;
          -  Any current medical, psychiatric, occupational, or substance abuse problems that, in&#xD;
             the opinion of the investigator, will make it unlikely that the participant will&#xD;
             comply with the protocol.&#xD;
&#xD;
          -  For Human Immunodeficiency Virus infected participants:&#xD;
&#xD;
               1. CD4+ count &lt;350 cells/microliter, OR&#xD;
&#xD;
               2. Acquired Immune Deficiency Syndrome-defining opportunistic infection or&#xD;
                  malignancies (except pulmonary TB).&#xD;
&#xD;
          -  Seated systolic/diastolic blood pressure assessed as vital sign [i.e. not from&#xD;
             electrocardiogram (ECG)] is less than 95/40 millimeters of Mercury (mmHg) or greater&#xD;
             than 145/95 mmHg at screening. Out-of-range blood pressure may be repeated twice with&#xD;
             at least 5 minutes intervening.&#xD;
&#xD;
          -  Seated heart rate assessed as vital sign (i.e. not from ECG) is lower than 40 beats&#xD;
             per minute (bpm) or higher than 110 bpm at screening. Out-of-range heart rate may be&#xD;
             repeated twice with at least 5 minutes intervening.&#xD;
&#xD;
          -  A clinically significant ECG abnormality at screening. NOTE: The following can be&#xD;
             considered not clinically significant:&#xD;
&#xD;
               1. mild first-degree atrio-ventricular block (P-R interval &lt;0.23 seconds);&#xD;
&#xD;
               2. right or left axis deviation;&#xD;
&#xD;
               3. incomplete right bundle branch block;&#xD;
&#xD;
               4. isolated left anterior fascicular block (left anterior hemiblock) in young&#xD;
                  athletic participants.&#xD;
&#xD;
          -  A list of commonly used prohibited medications with the features described below are&#xD;
             prohibited:&#xD;
&#xD;
               -  Use of medications active against Mtb within 3 months prior to the first dose of&#xD;
                  study drug.&#xD;
&#xD;
               -  Use of systemic immunosuppressive medications within 14 days prior to the first&#xD;
                  dose of study drug.&#xD;
&#xD;
               -  Use of strong inhibitors or strong inducers of cytochrome P450 (CYP) enzymes&#xD;
                  within 14 days prior to the first dose of study drug.&#xD;
&#xD;
               -  Use of inhibitors of phosphodiesterase (PDE) enzymes within 14 days prior to the&#xD;
                  first dose of study drug.&#xD;
&#xD;
               -  Use of medications known to affect the eye within 3 months prior to the first&#xD;
                  dose of study drug.&#xD;
&#xD;
               -  For Human Immunodeficiency Virus positive participants, use of medications listed&#xD;
                  in the protocol within 3 months prior to the first dose of study drug.&#xD;
&#xD;
          -  Participation in other clinical study(-ies) with investigational agent(s) within 6&#xD;
             months prior to trial start.&#xD;
&#xD;
          -  The following laboratory values from blood collected during the Screening Phase, which&#xD;
             represent Grade 2 or higher abnormalities per Division of Acquired Immune Deficiency&#xD;
             Syndrome (DAIDS) Toxicity Table Version 2.1, will be cause for exclusion:&#xD;
&#xD;
               -  Aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase ≥ 2.5x&#xD;
                  upper limit of normal (ULN) for local laboratory values&#xD;
&#xD;
               -  Total bilirubin ≥ 1.6x ULN&#xD;
&#xD;
               -  Creatinine ≥ 1.3x ULN&#xD;
&#xD;
               -  Hemoglobin &lt; 10 grams per deciliter (g/dL) [male] or 9.5 g/dL [female]&#xD;
&#xD;
               -  White Blood Cells &lt; 2,000 /cubic millimeter (mm3)&#xD;
&#xD;
               -  Platelets ≤ 100,000 /mm3&#xD;
&#xD;
               -  International normalized ratio of prothrombin time (INR) ≥ 1.5x ULN&#xD;
&#xD;
               -  Partial thromboplastin time (PTT) ≥ 1.66 ULN&#xD;
&#xD;
               -  Prothrombin time (PT) ≥ 1.25x ULN&#xD;
&#xD;
        Grade 2 or higher abnormalities in other laboratory parameters from blood or urine Grade 1&#xD;
        abnormalities, or abnormalities from laboratory parameters not included in the DAIDS&#xD;
        Toxicity Table Version 2.1, may lead to exclusion if the investigator considers them&#xD;
        clinically significant.&#xD;
&#xD;
          -  History of allergy or hypersensitivity to any of the study drugs or related&#xD;
             substances.&#xD;
&#xD;
          -  Positive urine drug screening for cocaine AND/OR amphetamines AND/OR opiates AND/OR&#xD;
             methamphetamines. Note: screening will also be conducted for cannabinoids and results&#xD;
             documented in the case report form; however, a positive test for cannabinoids is not&#xD;
             an exclusion criterion.&#xD;
&#xD;
          -  Female participants currently pregnant or lactating/nursing; OR having positive serum&#xD;
             pregnancy test during the Screening Phase OR planning a pregnancy within the 1 month&#xD;
             after first dose of study drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gates MRI</last_name>
    <role>Study Director</role>
    <affiliation>Bill &amp; Melinda Gates Medical Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gates MRI</last_name>
    <phone>+1 857 702 2108</phone>
    <email>clinical.trials@gatesmri.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gates MRI (Toll Free Number)</last_name>
    <phone>+1 866 789 5767</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Bellville</city>
        <state>Cape Town</state>
        <zip>7530</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Mowbray</city>
        <state>Cape Town</state>
        <zip>7700</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0087</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 29, 2019</study_first_submitted>
  <study_first_submitted_qc>November 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2019</study_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rifampicin-sensitive pulmonary tuberculosis</keyword>
  <keyword>TBA-7371</keyword>
  <keyword>Pulmonary tuberculosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

